Cargando…

Design, Synthesis, and Cytotoxicity Assessment of [(64)Cu]Cu-NOTA-Terpyridine Platinum Conjugate: A Novel Chemoradiotherapeutic Agent with Flexible Linker

Maximum benefits of chemoradiation therapy with platinum-based compounds are expected if the radiation and the drug are localized simultaneously in cancer cells. To optimize this concomitant effect, we developed the novel chemoradiotherapeutic agent [(64)Cu]Cu-NOTA-C3-TP by conjugating, via a short...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khosravifarsani, Meysam, Ait-Mohand, Samia, Paquette, Benoit, Sanche, Léon, Guérin, Brigitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469169/ https://www.ncbi.nlm.nih.gov/pubmed/34578470 http://dx.doi.org/10.3390/nano11092154

Ejemplares similares

In vivo behavior of [(64)Cu]NOTA-terpyridine platinum, a novel chemo-radio-theranostic agent for imaging, and therapy of colorectal cancer
por: Khosravifarsani, Meysam, et al.
Publicado: (2022)

Comparative study of (64)Cu/NOTA-[D-Tyr(6),βAla(11),Thi(13),Nle(14)]BBN(6-14) monomer and dimers for prostate cancer PET imaging
por: Fournier, Patrick, et al.
Publicado: (2012)

Synthesis and evaluation of (64)Cu-radiolabeled NOTA-cetuximab ((64)Cu-NOTA-C225) for immuno-PET imaging of EGFR expression
por: Xu, Xiaoxia, et al.
Publicado: (2019)

PACE4-Based Molecular Targeting of Prostate Cancer Using an Engineered (64)Cu-Radiolabeled Peptide Inhibitor()()
por: Couture, Frédéric, et al.
Publicado: (2014)

Comparison of the Effects of DOTA and NOTA Chelators on (64)Cu-Cudotadipep and (64)Cu-Cunotadipep for Prostate Cancer
por: Lee, Inki, et al.
Publicado: (2023)

Theranostic (64)Cu-DOTHA(2)-PSMA allows low toxicity radioligand therapy in mice prostate cancer model
por: Milot, Marie-Christine, et al.
Publicado: (2023)

(64)Cu-DOTHA(2)-PSMA, a Novel PSMA PET Radiotracer for Prostate Cancer with a Long Imaging Time Window
por: Milot, Marie-Christine, et al.
Publicado: (2022)

Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with (64)Cu Using NOTA and NODAGA
por: Tolmachev, Vladimir, et al.
Publicado: (2017)

Introduction of a Polyethylene Glycol Linker Improves Uptake of (67)Cu-NOTA-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide in Melanoma
por: Qiao, Zheng, et al.
Publicado: (2023)

Radionuclide Cisternography with [(64)Cu]Cu-DOTA
por: Greiser, Julia, et al.
Publicado: (2023)

Recent Advances in (64)Cu/(67)Cu-Based Radiopharmaceuticals
por: Krasnovskaya, Olga O., et al.
Publicado: (2023)

Positron Emission Tomography Imaging of CD105 Expression with a (64)Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA
por: Zhang, Yin, et al.
Publicado: (2011)

[(64)Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model
por: Poschenrieder, Andreas, et al.
Publicado: (2017)

Evaluation of [(64)Cu]Cu-NOTA-PEG(7)-H-Tz for Pretargeted Imaging in LS174T Xenografts—Comparison to [(111)In]In-DOTA-PEG(11)-BisPy-Tz
por: Poulie, Christian B. M., et al.
Publicado: (2021)

(64)Cu-ATSM/(64)Cu-Cl(2) and their relationship to hypoxia in glioblastoma: a preclinical study
por: Pérès, Elodie A., et al.
Publicado: (2019)

A preliminary clinical trial to evaluate (64)Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer
por: Lee, Inki, et al.
Publicado: (2021)

Harnessing (64)Cu/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy
por: Keinänen, Outi, et al.
Publicado: (2020)

Theragnostic (64)Cu/(67)Cu Radioisotopes Production With RFT-30 Cyclotron
por: Lee, Jun Young, et al.
Publicado: (2022)

[(64)Cu]Cu-DOTATATE PET metrics in the investigation of atherosclerotic inflammation in humans
por: Jensen, Jacob K., et al.
Publicado: (2022)

[(64)Cu]‐labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice
por: Schjoeth‐Eskesen, Christina, et al.
Publicado: (2015)

(64)Cu-based Radiopharmaceuticals in Molecular Imaging
por: Zhou, Yeye, et al.
Publicado: (2019)

Monitoring CD8a(+) T Cell Responses to Radiotherapy and CTLA-4 Blockade Using [(64)Cu]NOTA-CD8a PET Imaging
por: Kristensen, Lotte K., et al.
Publicado: (2020)

iEDDA Conjugation Reaction in Radiometal Labeling of Peptides with (68)Ga and (64)Cu: Unexpected Findings
por: Litau, Shanna, et al.
Publicado: (2018)

An abbreviated therapy-dosimetric equation for the companion diagnostic/therapeutic [(64/67)Cu]Cu-SARTATE
por: Laffon, Eric, et al.
Publicado: (2021)

(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry
por: Hansen, Anders E, et al.
Publicado: (2012)

The somatostatin receptor 2 antagonist (64)Cu-NODAGA-JR11 outperforms (64)Cu-DOTA-TATE in a mouse xenograft model
por: Rylova, Svetlana N., et al.
Publicado: (2018)

Selectivity of Terpyridine Platinum Anticancer Drugs for G-quadruplex DNA
por: Morel, Elodie, et al.
Publicado: (2019)

Escuelas de las dobles notas Op. 64 : para piano /
por: Moszkowski, Moritz, 1854.1925
Publicado: (1978)

Effect of intratumoral administration on biodistribution of (64)Cu-labeled nanoshells
por: Xie, Huan, et al.
Publicado: (2012)

Integrated (64)Cu therapy for the peritoneal dissemination of gastrointestinal cancer
por: Kurihara, Hiroaki
Publicado: (2018)

Pilot Study of (64)Cu(I) for PET Imaging of Melanoma
por: Jiang, Lei, et al.
Publicado: (2017)

(64)Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors
por: Mirzaei, Siroos, et al.
Publicado: (2019)

Effect of Liraglutide on Vascular Inflammation Evaluated by [(64)Cu]DOTATATE
por: Zobel, Emilie H., et al.
Publicado: (2021)

[(68)Ga]Ga-4HMSA a promising new PET tracer for imaging inflammation
por: Kahn Ali, Shigufa, et al.
Publicado: (2021)

Tissue acidosis does not mediate the hypoxia selectivity of [(64)Cu][Cu(ATSM)] in the isolated perfused rat heart
por: Baark, Friedrich, et al.
Publicado: (2019)

Molecular Dynamics Study of the Nanoindentation Behavior of Cu(64)Zr(36)/Cu Amorphous/Crystalline Nanolaminate Composites
por: Wu, Wen-Ping, et al.
Publicado: (2021)

Development of an automated production process of [(64)Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications
por: Liu, Tengzhi, et al.
Publicado: (2022)

Intrathecal [(64)Cu]Cu-albumin PET reveals age-related decline of lymphatic drainage of cerebrospinal fluid
por: Sarker, Azmal, et al.
Publicado: (2023)

In vitro and in vivo characterization of [(64)Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors
por: Liu, Tengzhi, et al.
Publicado: (2023)

Terpyridine–Cu(ii) targeting human telomeric DNA to produce highly stereospecific G-quadruplex DNA metalloenzyme
por: Li, Yinghao, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kirqlr21o20n7und4hl7fjtrdn